在实务中，我们发现无论在专利无效程序中还是在行政诉讼中，专利因"缺必特"条款被宣告无效的案例非常少，基于以上，本文拟对背后原因 进行分析。 《专利法实施细则》第二十三条第二款规定，独立权利要求应当从整体上反映发明或者实用新型的技术方案，记载解决技术问题的必要技术特征，该款俗 称"缺必特"条款（缺少必要技术特征下简称"缺必特"），"缺必特"条款是专利无效理由之一。 在专利无效程序及相应的行政诉讼程序中，必要技术特征要解决的技术问题是指说明书背景技术中声明的一个技术问题，而不是解决现有技术中存在的问 题，也不是解决背景技术中所列明的所有技术问题，这些在理论及司法实务已达成一致意见，不存在争议。 但在实务中，我们发现无论在专利无效程序中还是在行政诉讼中，专利因"缺必特"条款被宣告无效的案例非常少，基于以上，本文拟对背后原因进行分 析。 一、专利无效行政诉讼"缺必特"案件大数据分析 为有更准确、权威的结论，故不考虑专利无效决定中的数据，笔者仅以专利行政诉讼二审文书进行大数据分析。 在某案例库中，将引用法条限定为《中华人民共和国专利法实施细则（2023修订）》第二十三条第二款或《中华人民共和国专利法实施细则（2010修 ...

Core Viewpoint - The company, Nanwei Medical Technology Co., Ltd., is currently involved in a patent invalidation request initiated by Beijing Zhongke Shengkang Technology Co., Ltd., which may impact its patent rights and potential compensation from a previous infringement lawsuit [1][2]. Group 1: Case Background - The case is at the stage of acceptance and has not yet been reviewed [1]. - The company is the patent holder involved in the dispute [1]. - The patent in question is for a hemostatic clip (Patent No. 201410222753.7), which was applied for on May 23, 2014, and granted on November 18, 2015 [2]. Group 2: Previous Litigation - The company initiated a patent infringement lawsuit against Zhongke Shengkang, which resulted in a ruling that found Zhongke Shengkang guilty of infringement, ordering them to cease infringing activities and pay the company 700,000 yuan [2]. - Zhongke Shengkang has appealed the first-instance judgment to the Supreme People's Court, and the case is still under review [2]. Group 3: Impact on Company - If the patent is ultimately declared invalid, competitors may use the technology without compensation to the company, affecting the potential recovery from the previous lawsuit [1][3]. - The company asserts that the invalidation of the patent will not significantly impact its production and sales, as it has a robust core technology system that includes multiple patents and technical know-how [4]. - The company reported that its domestic sales of products utilizing the disputed patent were approximately 100 million yuan in 2024 [3].